PT2984108T - Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro - Google Patents

Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro

Info

Publication number
PT2984108T
PT2984108T PT147237291T PT14723729T PT2984108T PT 2984108 T PT2984108 T PT 2984108T PT 147237291 T PT147237291 T PT 147237291T PT 14723729 T PT14723729 T PT 14723729T PT 2984108 T PT2984108 T PT 2984108T
Authority
PT
Portugal
Prior art keywords
antibodies
diagnosis
cancer treatment
cancer
treatment
Prior art date
Application number
PT147237291T
Other languages
English (en)
Inventor
Luis Hernández Míguez José
Adan Plana Jaume
Maria Martínez Escolà Josep
Masa Álvarez Marc
Messeguer Peypoch Ramon
Mitjans Prat Francesc
Dakhel Plaza Sheila
Coll Manzano Antonio
Mª HERVAS VILLEGAS ROSA
Calvis Calpe Carme
Padilla García Laura
Tatiana Roque Navarro Lourdes
Barberà Ferrando Laura
Rivas Cañas Manuel
Original Assignee
Lykera Biomed S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lykera Biomed S A filed Critical Lykera Biomed S A
Publication of PT2984108T publication Critical patent/PT2984108T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT147237291T 2013-04-09 2014-04-09 Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro PT2984108T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382128 2013-04-09

Publications (1)

Publication Number Publication Date
PT2984108T true PT2984108T (pt) 2017-09-19

Family

ID=48049929

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147237291T PT2984108T (pt) 2013-04-09 2014-04-09 Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro

Country Status (11)

Country Link
US (1) US9914768B2 (pt)
EP (1) EP2984108B1 (pt)
CN (1) CN105873950A (pt)
CY (1) CY1119430T1 (pt)
DK (1) DK2984108T3 (pt)
ES (1) ES2639227T3 (pt)
LT (1) LT2984108T (pt)
PL (1) PL2984108T3 (pt)
PT (1) PT2984108T (pt)
SM (1) SMT201700402T1 (pt)
WO (1) WO2014167030A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI733772B (zh) * 2016-03-14 2021-07-21 美商身體邏輯股份有限公司 用於合成吲哚環核鹼基結合物之組成物及方法
KR102645432B1 (ko) * 2016-03-28 2024-03-11 (주)아모레퍼시픽 피부 세포 분화 촉진용 조성물 및 피부 세포 분화 촉진 물질의 스크리닝 방법
CN106943594A (zh) * 2017-03-29 2017-07-14 西安交通大学 Psoriasin抗体和LL‑37抗体在制备防治银屑病的药物中的应用
WO2024119068A2 (en) * 2022-12-02 2024-06-06 Ohio State Innovation Foundation S100a7 as a diagnostic marker and therapeutic target for disorders
EP4672980A2 (en) * 2023-03-01 2026-01-07 Bountica Ltd. An eco-friendly, sustainable food preservative
CN119638830B (zh) * 2024-12-24 2025-11-14 武汉爱博泰克生物科技有限公司 针对人s100a7蛋白的抗体、抗体对和试剂盒及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
ES2338774T3 (es) 2001-12-31 2010-05-12 Dana-Farber Cancer Institute, Inc. Expresion de psoriasina por las celulas epiteliales mamarias.
US20100021472A1 (en) 2008-07-25 2010-01-28 Geetha Srikrishna Methods for diagnosing and treating cancer
CN103201290B (zh) 2010-06-14 2016-09-28 莱克拉生物医学股份公司 S100a4抗体及其治疗用途

Also Published As

Publication number Publication date
ES2639227T3 (es) 2017-10-25
SMT201700402T1 (it) 2017-11-15
PL2984108T3 (pl) 2017-12-29
WO2014167030A1 (en) 2014-10-16
EP2984108B1 (en) 2017-05-31
US9914768B2 (en) 2018-03-13
LT2984108T (lt) 2017-11-10
CN105873950A (zh) 2016-08-17
DK2984108T3 (en) 2017-09-18
CY1119430T1 (el) 2018-03-07
EP2984108A1 (en) 2016-02-17
US20160289307A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
IL290972A (en) Anti-vista antibodies and fragments
IL255312A0 (en) Therapeutic and diagnostic methods for cancer
DK2956483T3 (da) Terapeutisk og diagnostisk mål for cancer omfattende dll3-bindende reagenser
PL2958945T3 (pl) Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
IL256025A (en) Methods of diagnosing and treating cancer
IL244422A0 (en) Anti-b7-h1 antibodies for treating tumors
BR112015028115A2 (pt) métodos e composições para o tratamento de câncer
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
HUE046505T2 (hu) Antitestkészítmények daganatkezelésre
EP3084419C0 (en) ADVANCED ULTRASONIC INSPECTION
BR112014032105A2 (pt) método para o tratamento de câncer
PT2976360T (pt) Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro
IL244089A0 (en) Diagnostic methods and compositions for treatment of glioblastoma
CL2015001049A1 (es) Terapia de combinación de anticuerpos anti-her3
BR112015025408A2 (pt) combinações de droga para tratar câncer
EP2967478A4 (en) ON THE BODY PORTABLE ELECTROMAGNETIC TOMOGRAPHIC IMAGING
PT3511004T (pt) Preparações combinadas para o tratamento de cancro
HRP20181561T1 (hr) Usmjerivi medicinski uređaj
PT3052525T (pt) Anticorpos anti-epcam e métodos de utilização
LT3563837T (lt) Terapija bakteriofagu
HRP20182041T1 (hr) Pripravci oksprenolola za liječenje raka
HUE047920T2 (hu) GD2-pozitív rák kezelésére szolgáló készítmények
PT3016682T (pt) Métodos para tratamento do cancro
EP2839068A4 (en) Clothes treatment apparatus
IL244632A0 (en) Cancer biomarker and diagnostic